BFC Planning’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.6K Hold
158
– – ﹤0.01% 2407
2026
Q2
$11K Hold
158
– – ﹤0.01% 2316
2026
Q1
$11.4K Hold
158
– – ﹤0.01% 1985
2025
Q4
$6.68K Hold
158
– – ﹤0.01% 2245
2025
Q3
$8.99K Hold
158
– – ﹤0.01% 1975
2025
Q2
$4.08K Sell
158
-89
-36% -$999 ﹤0.01% 2125
2025
Q1
$2.52K Hold
247
– – ﹤0.01% 2248
2024
Q4
$3.44K Hold
247
– – ﹤0.01% 2122
2024
Q3
$4.81K Buy
+247
New +$4.71K ﹤0.01% 2024

Other funds holding NKTR

BFC Planning's NKTR Position: Q3 2026 in Review

BFC Planning held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 158 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

BFC Planning first reported a position in NKTR in Q3 2024 and has held it in 9 quarters since. The position peaked at $11.4K in Q1 2026. 173 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • BFC Planning held 158 shares of Nektar Therapeutics worth $9.6K as of Q3 2026.
  • BFC Planning left its Nektar Therapeutics share count unchanged in Q3 2026.
  • Nektar Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2407 holding.
  • BFC Planning first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Nektar Therapeutics position peaked at $11.4K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.